In-hospital cardiac arrest in Intensive Care Unit versus non-Intensive Care Unit patients with COVID-19. A systematic review and meta-analysis

Georgios Mavrovounis; Maria Mermiri; Athanasios Chalkias; Vishad Sheth; Vasiliki Tsolaki; Konstantinos Gourgoulianis; Ioannis Pantazoulos

doi:10.1101/2021.05.08.21256885

Abstract

Aim To estimate the incidence of in-hospital cardiac arrest (IHCA) and return of spontaneous circulation (ROSC) in COVID-19 patients, as well as to compare the incidence and outcomes of IHCA in Intensive Care Unit (ICU) versus non-ICU patients with COVID-19.

Methods We systematically reviewed the PubMed, Scopus and clinicaltrials.gov databases to identify relevant studies.

Results Eleven studies were included in our study. The pooled prevalence/incidence, pooled odds ratios (OR) and 95% Confidence Intervals (95% CI) were calculated, as appropriate. The quality of the included studies was assessed using appropriate tools. The pooled incidence of IHCA in COVID-19 patients was 7% [95% CI: 4 – 11%; P < 0.0001] and 44% [95% CI: 30 – 58%; P < 0.0001] achieved ROSC. Of those that survived, 58% [95% CI: 42 – 74%; P < 0.0001] had a good neurological outcome (Cerebral Performance Category 1 or 2) and the mortality at the last follow-up was 59% [95% CI: 37 – 81%; P < 0.0001]. A statistically significant higher percentage of ROSC [OR (95% CI): 5.088 (2.852, 9.079); P < 0.0001] was found among ICU patients versus those in the general wards.

Conclusion The incidence of IHCA amongst hospitalized COVID-19 patients is 7%, with 44% of them achieving ROSC. Patients in the ICU were more likely to achieve ROSC than those in the general wards, however the mortality did not differ.

What this paper adds Section 1: What is already known on this subject

Mortality in COVID-19 patients ranges between 20% and 40%.
it has been reported that patients with COVID-19 have a high incidence of IHCA and higher mortality.
This paper aimed to calculate the proportion of COVID-19 patients who experience IHCA and their outcome, as well as compare the outcome of IHCA between ICU and non-ICU patients.

Section 2: What this study adds

Approximately 7% of hospitalized COVID-19 patients suffer from IHCA and 44% of those achieve ROSC.
The rate of ROSC was higher in ICU patients, but the rate of mortality did not differe between ICU and non-ICU patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=226262

Funding Statement

None received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

There was no need for IRB/oversight body approval as the current study constitutes a systemativ review and meta-analysis

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflict of Interest: None Declared
Funding: None
Data Availability: The data that support the findings of this study are available from the corresponding author (MM), upon reasonable request.